Are there clinical factors that can predict prolonged survival of patients receiving olaparib as maintenance therapy for BRCA-mutated ovarian cancer?

被引：0
|
作者：
Lieberman, Howard B. [1 ,2 ]
机构：
[1] Columbia Univ, Vagelos Coll Phys & Surg, Ctr Radiol Res, 630 W 168th St, New York, NY 10032 USA
[2] Columbia Univ, Mailman Sch Publ Hlth, Dept Environm Hlth Sci, New York, NY USA
来源：
TRANSLATIONAL CANCER RESEARCH | 2020年 / 9卷 / 02期
关键词：
D O I：
10.21037/tcr.2019.12.102
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：418 / 420
页数：3
相关论文
共 50 条
  • [1] Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers
    Labidi-Galy, S. I.
    Rouge, T. deLa Motte
    Derbel, O.
    Wolfer, A.
    Kalbacher, E.
    Olivier, T.
    Combes, J-D.
    Hu-Heimgartner, K.
    Tredan, O.
    Guevara, H.
    Heinzelmann-Schwarz, V.
    Fehr, M.
    de Castelbajac, V.
    Vaflard, P.
    Crivelli, L.
    Bonadona, V.
    Viassolo, V.
    Bazan, F.
    Rodrigues, M.
    Ray-Coquard, I. L.
    ANNALS OF ONCOLOGY, 2019, 30 : 410 - 410
  • [2] Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers
    Labidi-Galy, S. Intidhar
    Rouge, Thibault de La Motte
    Derbel, Olfa
    Wolfer, Anita
    Kalbacher, Elsa
    Olivier, Timothee
    Combes, Jean-Damien
    Heimgartner-Hu, Ketty
    Tredan, Olivier
    Guevara, Hemerson
    Heudel, Pierre-Etienne
    Reverdy, Thibaut
    Bazan, Fernando
    Heinzelmann-Schwarz, Viola
    Fehr, Mathias
    de Castelbajac, Victoire
    Vaflard, Pauline
    Crivelli, Louise
    Bonadona, Valerie
    Viassolo, Valeria
    Buisson, Adrien
    Golmard, Lisa
    Rodrigues, Manuel
    Ray-Coquard, Isabelle
    GYNECOLOGIC ONCOLOGY, 2019, 155 (02) : 262 - 269
  • [3] Overview: FDA Approval of Olaparib Maintenance for BRCA-Mutated Ovarian Cancer
    Saleh, Naveed
    Copur, Mehmet Sitki
    ONCOLOGY-NEW YORK, 2019, 33 (07): : 293 - 294
  • [4] Olaparib for BRCA-mutated advanced ovarian cancer
    de Lartigue, Jane
    JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY, 2015, 13 (06): : 206 - 208
  • [5] Real-world experience of olaparib as maintenance therapy in BRCA-mutated recurrent ovarian cancer
    Angela Cho
    Jeong-Yeol Park
    Shin-Wha Lee
    Dae-Yeon Kim
    Dae-Shik Suh
    Jong-Hyeok Kim
    Yong-Man Kim
    Young-Tak Kim
    Archives of Gynecology and Obstetrics, 2021, 304 : 1055 - 1063
  • [6] Real-world experience of olaparib as maintenance therapy in BRCA-mutated recurrent ovarian cancer
    Cho, Angela
    Park, Jeong-Yeol
    Lee, Shin-Wha
    Kim, Dae-Yeon
    Suh, Dae-Shik
    Kim, Jong-Hyeok
    Kim, Yong-Man
    Kim, Young-Tak
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2021, 304 (04) : 1055 - 1063
  • [7] Comparison of survival outcomes between olaparib and niraparib maintenance therapy in BRCA-mutated, newly diagnosed advanced ovarian cancer
    Kim, Ji Hyun
    Kim, Se Ik
    Park, Eun Young
    Kim, Eun Taeg
    Kim, Hyesu
    Kim, Sangeon
    Park, Sang-Yoon
    Lim, Myong Cheol
    GYNECOLOGIC ONCOLOGY, 2024, 181 : 33 - 39
  • [8] Olaparib for the treatment of BRCA-mutated advanced ovarian cancer
    Munroe, Marklie
    Kolesar, Jill
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2016, 73 (14) : 1037 - 1041
  • [9] BUDGET IMPACT FOR OLAPARIB MAINTENANCE THERAPY FOR BRCA-MUTATED PLATINUM SENSITIVE RECURRENT OVARIAN CANCER IN PERU
    Torres Toala, F. G.
    Solorzano, J.
    Baldi, J.
    VALUE IN HEALTH, 2018, 21 : S22 - S22
  • [10] BUDGET IMPACT FOR OLAPARIB MAINTENANCE THERAPY FOR BRCA-MUTATED PLATINUM SENSITIVE RECURRENT OVARIAN CANCER IN PANAMA
    Torres Toala, F. G.
    Solorzano, J.
    Baldi, J.
    Castillo-Fernandez, O.
    VALUE IN HEALTH, 2018, 21 : S22 - S22
12345